AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04988932
Drug: Inhaled nitric oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each increase of iNO dose is followed by a 10-minute monitoring period and a DSA examination. After reaching the highest effective dose of iNO or the maximum of 40 ppm another DSA is performed. iNO is going to be continued until normalisation of CVS or for a maximum period of 5 days. During iNO treatment a DSA will be performed every 24 hours, followed by a decrease of iNO to the next-lower level. If tapering the iNO concentration is associated with increasing vasospasm, iNO is going to be increased again to the last effective dosage. For cessation of iNO administration, dosage will be tapered every 30 minutes using the same dosage steps as for initiation of iNO treatment. If the duration of iNO treatment will be more than 32 hours, tapering intervals are prolonged to 4 hours. Cessation of iNO will be followed by a DSA.
Trial: NCT02739009
Drug: MOR106 single ascending doses, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02739009
Drug: Placebo single ascending doses, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02739009
Drug: MOR106 multiple ascending doses, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02739009
Drug: Placebo multiple intravenous administrations
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01073605
Drug: Genotonorm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 IU/kg/week or 0.03 mg/kg/day, daily subcutaneous injection
Trial: NCT03491462
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 matched placebo capsules taken 3 times daily
Trial: NCT02507648
Drug: Tamiflu®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet contains 75 mg oseltamivir
Trial: NCT04364230
Drug: NeoAg-mBRAF
RxNorm normalized name: B-Raf serine-threonine kinase (BRAF) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRAF 586-614 (V600E) peptide to which a histidine has been added to the N-terminus, resulting in BRAF 585-614 (V600E).
Trial: NCT02582892
Drug: Vit D
RxNorm normalized name: Tri-Vit Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day
Trial: NCT01288196
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 30-minute IV infusion of placebo
Trial: NCT01288196
Drug: CNTO 6785 1 mg/kg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 30-minute IV infusion of CNTO 6785 1 mg/kg
Trial: NCT01288196
Drug: CNTO 6785 3 mg/kg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 30-minute IV infusion of CNTO 6785 3 mg/kg
Trial: NCT01288196
Drug: CNTO 6785 10 mg/kg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 30-minute IV infusion of CNTO 6785 10 mg/kg
Trial: NCT01288196
Drug: Placebo SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single SC dose of placebo administered in up to 3 SC injections
Trial: NCT01019694
Drug: Combivent CFC-MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36/206 mcg Four times a day (QID)
Trial: NCT01019694
Drug: Combivent Respimat 20/100 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open label randomized parallel
Trial: NCT03789760
Drug: SaiLuoTong capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 subjects are randomly divided into two groups by 3:1. 375 subjects in the active group take two pills(120mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
Trial: NCT01543035
Drug: stop statin and switch to an antiretroviral drug with less impact on lipid metabolism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch from a boosted PI or efavirenz based ART regimen to etravirine 400 mg/day once daily for patients in need of lipid lowering drugs (statin) after one month wash out of statin
Trial: NCT00510536
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose to be determined by investigator
Trial: NCT03061136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02815332
Drug: BPX-01 1% Minocycline Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 1 gram applied once daily for 12 weeks
Trial: NCT02815332
Drug: BPX-01 2% Minocycline Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 1 gram applied once daily for 12 weeks
Trial: NCT02618616
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02682693
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 600 mg/m² every 2 or 3 weeks for 4 times
Trial: NCT00984893
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00984893
Drug: Any oral bisphosphonates marketed in Canada
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00600912
Drug: SMOFlipid®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
Trial: NCT03259464
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 sequential dose groups
Trial: NCT01834742
Drug: NER1006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single evening dose of 750mL solution containing 100g PEG3350 plus 6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
Trial: NCT01834742
Drug: NER1006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single evening dose of 750mL solution containing 100g PEG3350 plus 9g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
Trial: NCT01834742
Drug: NER1006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single evening dose of 750mL solution containing 75g PEG3350 plus 5.6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
Trial: NCT01834742
Drug: NER1006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350 and 56.6g sodium ascorbate.
Trial: NCT01834742
Drug: NER1006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate and 21.4g magnesium ascorbate.
Trial: NCT01834742
Drug: NER1006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 6g sodium sulphate and 33.9g sodium ascorbate.
Trial: NCT01834742
Drug: NER1006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single evening dose containing formulation selected from Part A of study. Single morning dose containing 29g PEG3350 and 4.8g sulphate and 23.3g ascorbic acid.
Trial: NCT00066482
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV over 1 hour. Children ≥ 12 months: Level 1: 1.2 g/m2/dose Level 2: 1.8 g/m2/dose Level 3: 2.4 g/m2/dose Children \< 12 months: Level 1: 40 mg/kg/dose Level 2: 60 mg/kg/dose Level 3: 80 mg/kg/dose Day 1 (Week 1, 4, 7, 10)
Trial: NCT00410332
Drug: Traumeel S
RxNorm normalized name: Traumeel S Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: homeopathic remedy
Trial: NCT00410332
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo drug, identical in size, form and taste as treatment remedy
Trial: NCT01602367
Drug: Placebo matching with BMS-823778
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, 0 mg, Once daily, 12 weeks
Trial: NCT02244255
Drug: FLOMAX® capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02244255
Drug: Ascending doses of HYTRIN® capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183038
Drug: Meloxicam low
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02183038
Drug: Meloxicam high
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02183038
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02183038
Drug: Meloxicam placebo low
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183038
Drug: Meloxicam placebo high
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183038
Drug: Naproxen sodium placebo
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00638716
Drug: CJC-1134-PC
RxNorm normalized name: CJC-1295
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 or 2.0 mg CJC-1134-PC
Trial: NCT00638716
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02608216
Drug: [18F]FLT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]FLT PET/CT scan, imaging tracer
Trial: NCT01073813
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg twice daily
Trial: NCT02080780
Drug: Clarithromycin XL
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin XL administered once daily on Days 4 through 9 as 2 x 500 mg tablets, 1000 mg per day, for a total of 6000 mg
Trial: NCT00676364
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dollop of matching placebo cream was applied under occlusive dressing for 15 mins prior to venipuncture
Trial: NCT02782559
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Color and size matched to active drug (sildenafil)
Trial: NCT00685399
Drug: AIN457
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIN457 subcutaneous dose
Trial: NCT00685399
Drug: AIN 457
RxNorm normalized name: Ainsliaea fragrans top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIN457 low dose (i.v)
Trial: NCT03028909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt-water solution containing no active ingredients.
Trial: NCT00983060
Drug: NIM811
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID in various doses (between 100 mg - 600 mg bid) + SOC (PEG IFN and RBV)
Trial: NCT01311076
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-329 placebo-matching tablets, orally, single dose, one day.
Trial: NCT02215395
Drug: NES/EE CVR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent administration of vaginal antimycotic medication (Miconazole Nitrate) on the pharmacokinetics of Nestorone (NES) and ethinyl estradiol (EE) delivered by a contraceptive vaginal ring (CVR)
Trial: NCT01863199
Drug: Lucentis every 12 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lucentis 0.5mg administered intravitreally every twelve weeks for 12 months
Trial: NCT02218047
Drug: Pegylated-Proline-interferon alpha-2b
RxNorm normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit \[Hct\]\<45%, platelets \[PLTs\]\<400 x 109/L and leukocytes \[WBCs\]\<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
Trial: NCT02218047
Drug: Best available therapy (BAT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best available therapy as selected by the investigator
Trial: NCT00627965
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tds
Trial: NCT02166398
Drug: UI15AML055MT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tab, PO
Trial: NCT02166398
Drug: Amosartan 5/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tab, PO
Trial: NCT03001635
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 26 patients will receive 0.9% normal saline infusion for 6h as placebo
Trial: NCT05037045
Drug: GLP-1 receptor agonist
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM
Trial: NCT02589626
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For blinding purposes
Trial: NCT00762268
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02546310
Drug: HTL0009936
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02546310
Drug: HTL0009936 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00044629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01533324
Drug: S-1 combined with Leucovorin
RxNorm normalized name: (S)-Leucovorin
DrugBank: (6R)-Folinic acid (DB03256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 capsules 80mg/m2/d BID one week on and one week off Leucovorin tablets 50mg/d BID one week on and one week off
Trial: NCT02216942
Drug: Endodontic treatment using Vitapex
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endodontic treatment using Vitapex
Trial: NCT02216942
Drug: Endodontic treatment using Guedes Pinto
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endodontic treatment using Guedes Pinto paste
Trial: NCT02423395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcium in muscle cramps in cirrhotic patients
Trial: NCT00542880
Drug: Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00542880
Drug: Seretide Diskus (salmeterol/fluticasone) 50/500 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00647465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02842580
Drug: 5 FLUOROURACYL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as a 2 hr infusion.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days. For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days.
Trial: NCT01323530
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral film-coated tablets.
Trial: NCT00245089
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01102257
Drug: Omega-3 EFA Supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 EFAs comprised of:~2000 mg EPA 1000 mg DHA
Trial: NCT02492984
Drug: Intravenous infusions of Xyntha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled subjects will be treated with intravenous infusions of Xyntha for: • On-Demand treatment, • Surgical Prophylaxis at a dose and frequency prescribed by the subject's treating physician in accordance with the Xyntha label and will be adjusted solely according to medical and therapeutic necessity.
Trial: NCT00003446
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003446
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00911469
Drug: AS902330
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3, 10, 30, 100 or 300 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30, 100, 300 µg or highest tolerated dose intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
Trial: NCT00911469
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or, 3, 10, 30, 100 or 300 µg intra-articular injection per subject in SAD cohorts and placebo or, 10, 30, 100, 300 µg or highest tolerated dose of AS902330 intra-articular injection per week for three weeks per subject in MAD cohorts.
Trial: NCT01676935
Drug: ABT-126
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT00140244
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01609855
Drug: Hyoscine Butyl Bromide 20mg/2 ml i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine Butyl Bromide 20mg/2 ml i.v.is administered at time of caecal intubation
Trial: NCT01609855
Drug: Saline 2 ml i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Saline 2 ml at time of caecal intubation
Trial: NCT00424619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 1 time bolus dose
Trial: NCT02467790
Drug: PEX168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEX 168: 200µg,Subcutaneous,one time.
Trial: NCT00083759
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00921557
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet taken once weekly
Trial: NCT00656292
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg po/nasogastric tube (NG) every day for 6 days
Trial: NCT00656292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill po/NG every day x 6 days
Trial: NCT04441528
Drug: Baby shampoo
RxNorm normalized name: BABY SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baby will be used in 24 patients for 8 weeks and will be discontinued in the following 4 weeks.
Trial: NCT02564900
Drug: DS-8201a (DP1)
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-8201a to be administered via intravenous (IV) dose. DS-8201a (DP1) was used for the Dose Escalation phase and for Dose expansion Parts 2a, 2b, 2c, and 2d.
Trial: NCT02564900
Drug: DS-8201a (DP)
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-8201a (DP) is to be administered via intravenous (IV) dose.
Trial: NCT00281788
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00109031
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is administered at a total dose of 100 mg/kg given in 1 dose on Day -2
Trial: NCT00463047
Drug: Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly assigned in a 1:1 ratio either to titrate immediate-release oxycodone first and to titrate FBT second, or to titrate FBT first and immediate-release oxycodone second, followed by 2 double-blind crossover treatment periods (in randomized order). For the double-blind treatment period of the study involving FBT administration, a patient is randomly assigned to receive FBT at the 200, 400, 600, or 800 mcg strength found to be successful during open-label titration. For the double-blind treatment period of the study to which a patient is randomly assigned to receive immediate-release oxycodone, the patient will receive immediate-release oxycodone at the strength (15, 30, 45, or 60 mg) found to be successful during open-label titration.
Trial: NCT02807727
Drug: Modified Ringers Lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous bolus dose of 1.5 ml/kg over 3 minutes
Trial: NCT02384746
Drug: MLN9708
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be treated in 3 dose cohorts of MLN9708, at 2.3, 3, and 4 mg orally on days 1, 4, 8, and 11 every 21 days.
Trial: NCT00109031
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as one daily intravenous bolus.
Trial: NCT01834885
Drug: QVA149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 via inhaler twice a day
Trial: NCT01585740
Drug: 0.9% Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid fluid
Trial: NCT01585740
Drug: Ringer's Lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid fluid
Trial: NCT02729766
Drug: Placebo P-Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000412
Drug: Placebo Alendronate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01985841
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Endoxan
Trial: NCT03076970
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral tablet -given with single lasmiditan tablet and with single sumatriptan tablet.
Trial: NCT02219893
Drug: MOC31PE Immunotoxin
RxNorm normalized name: hepatitis B immunoglobin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who meet inclusion criteria will be treated with a single intraperitoneal MOC31PE immunotoxin instillation for 6 hours on the first day after CRS and HIPEC
Trial: NCT04421287
Drug: Zhenyuan capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25g/ tablets, 2 tablets / TID, for 12 weeks